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Abstract
Summary To demonstrate the clinical comparability between RGB-10 (a biosimilar teriparatide) and the originator, a compar-
ative pharmacokinetic trial was conducted. The study was successful in establishing bioequivalence. Marketing authorisation for
RGB-10 (Terrosa®) was granted by the European Medicines Agency in 2017.
Introduction Teriparatide, the first bone anabolic agent, is the biologically active fragment of human parathyroid hormone. The
imminent patent expiry of the originator will open the door for biosimilars to enter the osteology market, thereby improving
access to a highly effective, yet prohibitively expensive therapy.
Methods Subsequent to establishing comparability on the quality and non-clinical levels between RGB-10, a biosimilar
teriparatide, and its reference product (Forsteo®), a randomised, double-blind, 2-way cross-over comparative study (duration:
four days) was conducted in 54 healthy women (ages: 18 to 55 years) to demonstrate the pharmacokinetic/pharmacodynamic
(PK/PD) equivalence and comparable safety of these products. Extents of exposure (AUC0-tlast) and peak exposure (Cmax), as
measured by means of ELISA, were evaluated as co-primary PK endpoints, and serum calcium levels, as measured using
standard automated techniques, were assessed for PD effects. Safety was monitored throughout the study.
Results The 94.12% CIs for the ratio of the test to the reference treatments, used due to the two-stage design (85.20–98.60% and
85.51–99.52% for AUC0-tlast and Cmax, respectively), fell within the 80.00–125.00% acceptance range. The calcium PD param-
eters were essentially identical with geometric mean ratios (GMRs) of 99.93% and 99.87% for AUC and Cmax, respectively.
Analysis of the safety data did not reveal any differences between RGB-10 and its reference.
Conclusion Based on the high level of similarity in the preclinical data and the results of this clinical study, marketing authori-
sation for RGB-10 (Terrosa®) was granted by the European Medicines Agency (EMA) in 2017.
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Introduction
Recombinant human teriparatide is the biologically active N-
terminal 34-amino acid fragment of the 84-amino acid native
parathyroid hormone [PTH (1–84)]. Since it is produced in
Escherichia coli (E. coli), the introduction of Forsteo® in
2003marked the beginning of the biologic era in the treatment
of osteoporosis.
The skeletal effects of teriparatide depend on the pattern of
systemic exposure. While continuous exposure to excessive
amounts of parathyroid hormone, as seen in hyperparathyroid-
ism, triggers bone resorption, intermittent elevations result in a
bone anabolic response [1]. Two phases may be distinguished
in the effect of intermittently administered PTH [2]. The
prompt increase in formation markers suggests that the first
few months of PTH treatment, often referred to as the anabolic
window, are predominantly characterised by an increase in
bone formation. However, at a later stage, bone formation be-
comes more remodelling-dependent [3], with bone formation
favoured over bone resorption, thereby resulting in a net gain of
bone deposition in each basic multicellular unit [4]. The bene-
ficial effects of teriparatide on bone density, microarchitecture
and bone geometry are seen predominantly in the cancellous
skeleton [5]. In the cortical bone envelope, intermittent PTH
* E. Jókai
e.jokai@richter.hu
1 Semmelweis University, Budapest, Hungary
2 Gedeon Richter Plc, 19-21 Gyömrői út, Budapest H-1103, Hungary
Osteoporosis International (2019) 30:675–683
https://doi.org/10.1007/s00198-018-4741-0
The first biosimilar approved for the treatment of osteoporosis: results
of a comparative pharmacokinetic/pharmacodynamic study
The Author(s) 2018
stimulates both endocortical and periosteal bone formation [3].
At cortical skeletal sites, teriparatide increases porosity, thereby
potentially decreasing BMD; however, the reduction in BMD
is not accompanied by diminished bone strength because the
increased porosity occurs only in the inner one third of the
bone, where the mechanical effect is minimal. Other positive
effects of teriparatide at the cortical bone, namely, changes in
bone geometry and microarchitecture, effectively counterbal-
ance any increase in cortical porosity [5]. Clinically, the meta-
bolic effects of teriparatide translate into improved bone min-
eral density (BMD) at vertebral and femoral skeletal sites as
well as a reduced incidence of vertebral and non-vertebral fra-
gility fractures [6]. Based on a meta-analysis by Murad et al. of
all anti-osteoporotic agents, teriparatide had the highest proba-
bility of being ranked as most effective and had the highest
reduction in the risk of vertebral, non-vertebral and hip frac-
tures [7]. Although clinical studies adequate to assess the effect
of teriparatide on the risk of hip fractures are lacking and are
unlikely to be conducted, there is evidence suggesting that
teriparatide is associated with beneficial effects on the hip in
patients with osteoporosis [8].
Teriparatide is indicated for the treatment of patients
with a high risk for fracture (in particular, men and post-
menopausal women with osteoporosis, as well as patients
with glucocorticoid-induced osteoporosis).
When the period of market exclusivity protecting the inno-
vator biopharmaceutical has expired, biosimilars can be intro-
duced to the market. Since the reference product is facing
patent expiry in the near future, the development of the first
biosimilar teriparatide was initiated to offer a less costly treat-
ment alternative for patients afflicted with severe osteoporosis.
The regulatory requirements for approving biosimilars have
been constantly evolving, and the extensive experience
amassed over the last 10 years has helped to shape the present
criteria laid down in the scientific guidelines issued by the
European Medicines Agency (EMA). This clinical pro-
gramme was designed to conform to the most recent regula-
tory requirements.
The objective of the clinical study was to demonstrate the
clinical comparability of RGB-10 and reference teriparatide
after having established a high level of similarity between
them on the quality and non-clinical levels (data on file).
Materials and methods
The study protocol followed all relevant regulatory guide-
lines, especially the Guideline on similar biological medic-
inal products [9] and the Guideline on the investigation of
bioequivalence [10] and was approved by the Office for
Research Eth i cs Commi t t ee s Nor thern I re land
(ORECNI), Lisburn, which is responsible for the study
location at Celerion, a centre that specialises in clinical
pharmacology studies (Belfast, Northern Ireland). The trial
identifiers are EudraCT number 2013-004040-31 and
ClinicalTrials.gov identifier NCT02223416. The details
of the clinical trial were subject to extensive regulatory
discussions. All participants gave their written informed
consent prior to the initial study-related assessments. The
performance and supervision of this trial followed the prin-
ciples of Good Clinical Practice (GCP) as laid down in
ICH E 6 [11]. The study was conducted in accordance with
the ethical requirements referred to in EU directive
2001/20/EC [12] and the ethical principles set forth in the
Declaration of Helsinki [13].
Subjects and design
From August 2014 to January 2015, 54 healthy adult female
volunteers, 18–55 years of age, were recruited for this
randomised, double-blind, two-period, two-sequence cross-
over comparative pharmacokinetic (PK) trial. In order to stan-
dardise the study subject population and to ensure homogene-
ity, the study was performed in healthy adult pre-menopausal
female subjects. The pharmacokinetics of the reference had
been characterised across a broad age range, and no differ-
ences were identified. In addition, there are no literature data
suggestive of a difference in PTH receptor density between
osteoporotic and healthy individuals. Consequently, it was
deemed appropriate to extrapolate the data generated in
healthy women to the target population of people diagnosed
with osteoporosis. A BMI of 18.5–27.0 kg/m2 and the absence
of any signs of clinically significant illness constituted the
main eligibility criteria. Women of childbearing potential
had to use medically acceptable means of birth control (other
than hormonal contraceptives) and to agree to continue its use
during the study and for at least 28 days after the last dosing.
The main exclusion criteria included known osteoporosis, the
history or presence of bone diseases (Paget’s disease, bone
carcinoma or bone metastases), any significant endocrine (in-
cluding thyroid and parathyroid gland) disease and hypercal-
ciuria and/or nephrolithiasis, urolithiasis in the past 5 years,
serum alkaline phosphatase levels exceeding the upper limit of
the normal range, as well as any prior or planned radiation
therapy involving the skeleton. Subjects with prior exposure
to teriparatide or any other PTH analogue product or with a
history of sensitivity to E. coli-derived proteins were also
excluded.
Subjects were randomised (1:1, using a computer-
generated list) to treatment sequences AB or BA, treatment
A corresponding to a single-dose of RGB-10 and treatment B
representing a single injection of reference. There were two
dosing days: period 1 day 1 and period 2 day 1, which were
separated by a washout period of 24 h. In both study periods,
the injections were administered into the abdomen universally
for all volunteers at hour 0 in the early morning. In each
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period, blood sampling for PK evaluation was performed be-
fore dosing and at pre-defined time points of 10, 20, 25, 30,
35, 40, 50, 60, 70, 80, 90, 120, 180 and 240 min post-dose.
Laboratory assessments for serum Ca were performed pre-
dose and at 120, 180 and 240 min and 6, 8 and 12 h post-
dose in each period. Safety was monitored throughout the
study.
Methods
RGB-10 (drug substance manufactured by Richter-Helm,
Bovenau, Germany; drug product manufactured by
Gedeon Richter Plc., Debrecen, Hungary) was supplied
as a fixed 20 μg/80 μL solution for injection in a cartridge
inserted in a reusable, multi-dose pen injector (ServoPen
Fix®, manufactured by Ypsomed AG, Switzerland). A sin-
gle RGB-10 cartridge of 2.4 mL contains 600 μg of
teriparatide (corresponding to 250 μg per ml). The refer-
ence was supplied using the marketed pre-filled pen,
Forsteo® (Lilly France S.A.S, Fegersheim, France) con-
taining the same amount and concentration of teriparatide
per single injection. The same type of needle, a BD Micro-
Fine™ + Pen Needle (0.25 mm (31G), TW, 8 mm), was
used for both devices. The two injection devices were com-
parable in terms of dose accuracy. Since the appearance as
well as the handling of the two devices differed, the study
drugs were injected by an unblinded study team member to
ensure the trial design was double-blind for the investiga-
tor and the volunteers.
A commercially available, high-sensitivity human PTH(1-
34) ELISA kit from Immutopics, Inc. (San Clemente,
California, Cat no. 60-3900) was specially adapted to the ref-
erences Teriparatide RGB-10 (rhPTH(1-34), Gedeon Richter)
and Forsteo® (rhPTH(1-34), Eli Lilly) and GLP validated with
respect to the assay parameters required by the applicable
regulations. The lower limit of quantification (LLQ) was set
at 6.0 pg/mL. The primary PK endpoints were AUC0-tlast and
Cmax. The time to reach maximum concentration (tmax), the
apparent terminal elimination half-life (t1/2) and theAUC from
time zero extrapolated to infinity (AUC0-inf), AUC%extrap, the
time to last measurable concentration (tlast), the elimination
rate constant (kel), the apparent total plasma clearance (CL/
F), and the volume of distribution (Vz/F) were measured as
secondary PK parameters.
Serum calcium was measured using Calcium Gen.2, an
in vitro test for the quantitative determination of calcium in
human serum, and a Cobas 6000 c501 analyser (Roche
Diagnostics A/S, Mannheim, Germany). Under alkaline con-
ditions, calcium ions form a complex with 5-nitro-5′-methyl-
BAPTA (NM-BAPTA), which reacts in a second step with
EDTA. The resulting change in absorbance is directly propor-
tional to the calcium concentration and is measured photomet-
rically. The lower limit of quantitation is 0.8 mg/dl, and the
average CV is 1.85%. Total serum calcium values were
corrected for albumin (ALB) using the formula: Measured
Ca (mmol/L) + ((40-ALB (g/L)) * 0.02).
The safety and local tolerance of RGB-10 were com-
pared to those of the reference product through evaluating
the findings from physical examinations, vital sign mea-
surements, electrocardiograms (ECGs), pulse oximetry, the
recording of adverse events (AEs), assessing injection site
reactions and clinical laboratory tests. Immunogenicity
was not investigated in this study, since neither the sample
size nor the duration of the trial would have allowed us to
collect any clinically relevant data on the immunogenic
potential of RGB-10.
Sample size calculation
Due to the limited amount of literature data available on the
variability characterising teriparatide pharmacokinetics, a two-
stage design was selected. Two-stage designs are applied when
the variability is unknown prior to the study and allow the
modification of the sample size at an interim analysis with full
control of the type I error [14]. If the stage 1 sample size turns
out to be smaller than appropriate for the variability estimated
based on the stage 1 data, further subjects can then be enrolled
in the second stage. The sample size pre-determined for stage 1
was based on an expected test/reference ratio of 0.95–1.05 and
an intra-subject CV% value of 27% (for both AUC and Cmax),
values that are consistent with the total CV% in the literature
[15–17]. Allowing for 6 potential drop-outs, a sample size of 56
subjects was defined for stage 1, of which 50 had to be
evaluable to achieve a power of at least 90% using the α-
level of 0.0294; i.e. a 94.12% confidence interval (CI) instead
of the usual 90% CI, due to the type I error control for the two-
stage design. The standard bioequivalence (BE) acceptance
range of 80.00–125.00% was applied. This approach allowed
for stopping for equivalence at interim and for sample size
reassessment [10].
Statistical analyses
The primary endpoints were the 94.12% confidence inter-
vals of the ratios of the geometric means (test/reference)
derived from the analyses on the natural log (ln)-trans-
formed PK parameters AUC0-tlast and Cmax of the test and
reference formulations of teriparatide. ANOVA was per-
formed on the ln-transformed values of AUC0-tlast, AUC0-
inf, Cmax and t1/2. Since the subjects were dosed in groups,
the ANOVA model included sequence, group, period
nested within group, treatment and treatment*group inter-
action as fixed effects, and subject nested within
group*sequence as a random effect. If the treatment*group
interaction was not statistically significant at the 5% level,
the interaction term was dropped from the model. If a
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statistically significant interaction was found, results for
those PK parameters that showed interactions were to be
presented by group as well as combined. Each ANOVA
included calculation of the least square means (LSMs),
the difference between treatment LSMs and the standard
error associated with this difference.
A further type of ANOVA analysis without the group factor
was also performed for robustness reasons.
Safety variables were summarised by treatment arm,
and no inferential statistics were analysed. The appropri-
ate non-compartmental PK parameters were calculated
from the plasma teriparatide concentration-time data
using Phoenix® WinNonlin® version 6.3. All descriptive
statistical analyses were performed using SAS 9.3
software.
Results
Although 56 subjects were predefined for stage 1 due to
small cohort sizes (thus potentially resulting in a signifi-
cant t reatment-by-group interact ion and thereby
compromising the primary PK analysis), the last cohort,
which would have consisted of two subjects only, was
not enrolled. Consequently, a total of 54 subjects were
randomised to study treatments and analysed for safety.
All subjects satisfied all inclusion criteria and fulfilled
none of the exclusion criteria. The demographic data for
all 54 patients showed a mean age of 29.2 ± 8.3 years, a
height of 164.2 ± 6.0 cm, a weight of 62.1 ± 7.1 kg and a
BMI of 23.0 ± 2.0 kg/m2. One subject withdrew premature-
ly after period 1 for personal reasons. Two further subjects
were excluded from the PK analysis as a result of events
compromising the evaluation of their PK profiles; one had
measurable pre-dose concentrations greater than 5% of the
Cmax in both periods (an exclusion criterion predefined in
the statistical analysis plan), and the other lacked several
PK samples in the absorption phase. Therefore, the final
PK population for the primary endpoints of AUC0-tlast and
Cmax comprised 51 subjects.
After reviewing the results from the interim analyses, it
was not necessary to proceed to stage 2 because the data
variability was less than anticipated based on the literature,
and concluding on equivalence was possible using only
stage 1 data. If the study had continued to stage 2, due to
obtaining a power of less than 90%, the sample size would
have been re-estimated based on stage 1 intrasubject CV
PK results, an expected power of at least 90%, and the
initially assumed ratio of 0.95–1.05 using an alpha level
of 0.0294 (i.e. using a 94.12% CI). A maximum of 58
subjects (between 1 and 58 subjects) would have been en-
rolled in stage 2, and the same procedures would have been
followed for stage 2 subjects as those followed for subjects
in stage 1. Bioequivalence would have been evaluated for
the second time after the completion of stage 2 based on
data from both stages at an alpha level of 0.0294 (using a
94.12% CI).
Pharmacokinetics
Teriparatide was rapidly absorbed following subcutaneous
(s.c.) administration, and measurable concentrations were
observed as early as 10 min after dosing in all subjects. A
summary of the PK parameters for RGB-10 and the ref-
erence drug is presented in Table 1, and the arithmetic
mean teriparatide serum concentration–time profiles are
displayed in Fig. 1.
Throughout most of the sampling interval, mean concen-
trations were slightly lower for RGB-10 than for the reference.
In more than half of the subjects, individual plasma
teriparatide concentration–time profiles showed multiple ab-
sorption peaks for either RGB-10 or the reference product, or
following both treatments.
Statistical comparisons of plasma teriparatide PK parame-
ters are summarised in Table 2.
Bioavailability and mean concentrations after the adminis-
tration of RGB-10 appeared to be slightly lower than those for
the reference. Based on the geometric mean ratios (GMR), the
extent, total extent and peak teriparatide exposure in plasma
(as measured byAUC0-tlast, AUC0-inf and Cmax) were 8 to 10%
Table 1 Pharmacokinetic parameters following single 20 μg/80 μL s.c.




a 91.8 (40.9%) 99.0 (35.0%)
AUC0-inf (pg*h/mL)
a 103 (37.8%) 114 (29.7%)
AUC%extrap (%)
b 10.9 ± 5.54 10.6 ± 5.15
Cmax (pg/mL)
a 82.4 (40.1%) 89.2 (37.1%)
tmax (h)
c 0.334 (0.166, 0.585) 0.417 (0.167, 0.667)
tlast (h)
b 2.49 ± 0.729 2.58 ± 0.707
t1/2 (h)
b 0.701 ± 0.287 0.757 ± 0.285
kel (1/h)
b 1.11 ± 0.331 1.03 ± 0.339
CL/F (L/h)b 207 ± 83.2 183 ± 54.3
Vz/F (L)
b 203 ± 96.1 198 ± 87.4
GM geometric mean; GCV% geometric coefficient of variation, AM ar-
ithmetic mean, SD standard deviation
a Presented as GM (GCV%)
b Presented as AM ± SD
c Presented as Median (Minimum, Maximum)
dN = 50 for AUC0-inf, AUC%extrap, t1/2, kel, CL/F, Vz/F because kel value
could not be estimated for subject 32
eN = 49 for AUC0-inf, AUC%extrap, t1/2, kel, CL/F, Vz/F because kel values
could not be estimated for subjects 32 and 41
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lower for RGB-10 than for the reference. Nevertheless, the
94.12% CIs for the ratio of the test to the reference treatments
fell entirely within the 80.00–125.00% acceptance range for
BE. The data derived from the second ANOVA analysis that
did not include the group factor virtually coincided with those
of the ANOVA model that did include the group effect, thus
confirming that the group factor had no impact on the statis-
tical results.
Regarding the secondary PK endpoints, no clinically sig-
nificant differences were detected between the treatments. The
half-life was 9% shorter for RGB-10 than for the reference,
and there was a small (4.5 min) difference in plasma
teriparatide median tmax values. The mean teriparatide CL/F
value was approximately 13% higher for RGB-10 than for the
reference product, whereas the mean Vz/F values were similar
between the two treatments.
In conclusion, the 94.12% CIs for the GMRs (test/reference)
of primary PK endpoints AUC0–last (85.20–98.60%) and Cmax
(85.51–99.52%) were contained within the standard BE
acceptance range of 80–125%. Based on these statistical results,
RGB-10 can be considered as bioequivalent to its reference.
Pharmacodynamics
The serum calcium concentration–time curves for RGB-10
and the reference were characterised by computing the phar-
macodynamic (PD) parameters AUC0-tlast, Cmax and tmax.
Descriptive statistics of the parameters are presented in
Table 3.
Statistical analysis of all serum calcium PD parameters
showed close similarity between RGB-10 and the reference
with GMRs of 99.93 and 99.87% for AUC and Cmax, respec-
tively, and a median difference of 0.001 for tmax.
The relationship between the pharmacokinetics and the
pharmacodynamics of RGB-10 and the reference is displayed
in Fig. 2.
PK and PD profiles indicate that the concentration–effect
relationships for the two treatments are not different and that
Fig. 1 Pharmacokinetic profiles
following single 20 μg/80 μL s.c.
administrations of RGB-10 and
the reference teriparatide
Table 2 Statistical comparisons




Parameters RGB -10 Reference GMR%b 94.12% CIc Intra-subject CV%d
Cmax (pg/mL) 83.19 90.18 92.25 85.51–99.52 19.37
AUC0-tlast (pg*h/mL) 92.44 100.86 91.66 85.20–98.60 18.63
AUC0-inf (pg*h/mL) 103.89 115.66 89.82 83.75–96.33 17.48
t1/2 (h) 0.65 0.72 91.39 83.28–100.29 23.38
a Geometric least-squares means (LSMs) are calculated by exponentiation of the treatment LSMs derived from the
ANOVA
bGeometric mean ratio (GMR) = 100 * (RGB-10/reference)
c Confidence interval (CI) inherent to the application of the two-stage design
d Intra-subject coefficient of variation (CV) was calculated as 100 × square root(exp[residual variance] − 1)
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equivalent exposure results in an equivalent response, thus
supporting the biosimilarity.
Safety
All subjects who received at least 1 dose of the study medica-
tion (i.e., a total of 54 subjects) were included in the safety
analysis. There were no deaths, serious adverse events (SAEs)
or subject discontinuations due to AEs. Overall, a total of 127
treatment emergent adverse events (TEAEs) were experienced
by 43 (80%) subjects participating in this study. The most
common events reported during the study were nausea (20
[37%] subjects) followed by dizziness (15 [28%] subjects),
headache (13 [24%] subjects) and injection site erythema
(12 [22%] subjects). There were no remarkable or new and
unexpected findings from the safety assessments, and RGB-
10 and the reference had similar safety profiles and exhibited
no significant differences in the type or incidence of AEs
recorded. The most commonly reported (≥ 10%) TEAEs for
RGB-10 and the reference are presented in Table 4.
It can be concluded that single 20 μg/80 μL s.c. injections
of RGB-10 are safe, and the nature and incidence of adverse
events coincided with those recorded for the reference. No
new safety concerns emerged from this study.
Discussion
Here, we report the clinical comparability of two teriparatide
products based on a comparative single-dose, two-way cross-
over study in healthy female pre-menopausal adults following
single s.c. administrations of RGB-10 and the reference drug.
No product-specific regulatory guidelines explicitly define




20 μg/80 μL s.c. injections of
RGB-10 and reference
teriparatide (reference)
AUC0-tlast (h*mmol/L) Cmax (mmol/L) tmax (hr)
RGB-10 Reference RGB-10 Reference RGB-10 Reference
N 53 53 53
Mean 27.60 27.62 2.35 2.35 5.21 5.03
SD 0.72 0.71 0.07 0.06 2.94 3.14
CV (%) 2.6 2.6 2.9 2.6 56.4 62.4
SEM 0.10 0.10 0.01 0.01 0.40 0.43
Minimum 26.3 26.0 2.22 2.21 0.00 0.00
Median 27.56 27.56 2.34 2.34 6.00 6.00
Maximum 28.9 28.8 2.51 2.46 12.0 12.0
Geom. mean 27.59 27.61 2.35 2.35 5.83 5.43
Geom. CV(%) 2.6 2.6 2.9 2.6 33.2 45.1
95% lower CI 27.40 27.43 2.33 2.33 4.40 4.16
95% upper CI 27.79 27.82 2.37 2.37 6.02 5.89
Fig. 2 Serum calcium
concentrationsc and plasma
teriparatide concentrations
following single 20 μg/80 μL s.c.
doses of RGB-10 and the refer-
ence teriparatide. a Formula used
for calcium correction: Measured
Ca (mmol/L) + ((40-ALB
(g/L)) * 0.02). b Baseline samples
for serum calcium were collected
within 2.5 h prior to the adminis-
tration of single 20 μg/
80 μL subcutaneous injections of
RGB-10 and the reference
teriparatide. c Serum calcium
concentrations (mmol/L) are giv-
en as the means ± SE
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teriparatide. Moreover, no prior development programmes ex-
ist that could have been followed since RGB-10 is the first
biosimilar teriparatide that has been granted marketing autho-
risation. Only some overarching regulatory guidance was
available at the timewhenRGB-10 development was planned.
In 2004, a dedicated route was introduced for biosimilars,
thus establishing a solid legal framework for their approval in
the EU. The more than 10 years of expertise acquired since
then has allowed EU regulators to integrate experience-based
knowledge with the initial science-driven concept shaping
current requirements for approval [18]. The basic principle
underlying the development of a biosimilar product is its com-
parability with the reference product; this is assessed using a
comparability exercise, which is the comparative testing per-
formed at all stages of the biosimilar development (i.e., on
quality, non-clinical and clinical levels) [19]. Based on the
EMA requirements, comparability testing is conceived as a
step-wise process, which is tailored to each product; that is,
knowledge from the initial quality comparability studies is
used to determine the extent and type of non-clinical and
clinical studies that are required in the next step of the de-
velopment [18]. Consistently, the design of the clinical de-
velopment programme considers the nature and character-
istics of the medicine and its intended use and how compa-
rable the profile of the biosimilar medicine is to that of the
reference product. Consequently, the closer the profiles of
the biosimilar and reference products and the higher the
similarity (as demonstrated through appropriate studies;
e.g., comparative quality, biological and receptor-binding
assays as well as in vitro studies) are, the more a tailored
clinical trial programme can be accepted by the EMA [19].
For simpler molecules with a well-established action (e.g.,
filgrastim) and where comparative quality and non-clinical
data are solid, it may be sufficient to compare the effect of
the biosimilar and the reference medicine based on PK and
PD studies in healthy volunteers [18].
Due to its low molecular weight and structural simplicity,
teriparatide qualifies as a very simple molecule. In this case,
the quality and non-clinical profiles of the biosimilar and ref-
erence products were close enough to lend legitimacy to the
application of a more tailored clinical trial programme. This
new development approach is reflected in the clinical study,
which was designed to establish clinical comparability be-
tween RGB-10 and its reference.
The results of this study showed that the PK profile of
RGB-10 is consistent with that of the originator drug. The
statistical analysis of the PK data formally established BE
between the two drugs, with the 94.12% CIs for the primary
endpoints (AUC0-tlast and Cmax) falling entirely within the
predefined equivalence margins of 80–125%.
The multiple-peak phenomenon detected in this study was
also observed by Liu et al. [20], who described double peaks
in two thirds of their study subjects following single and mul-
tiple s.c. doses of teriparatide; the first peak appeared within 5
to 20 min, and the second appeared within 30 to 60 min post-
dose. A double-peak profile was also reported following the
s.c. administration of recombinant human PTH(1–84). Plasma
and serum concentration time profiles of recombinant human
PTH(1-84) and its synthetic N-terminal fragment teriparatide
showed similar double-peak profiles, with no temporal differ-
ence in the appearance of both peaks [21, 22]. It was sug-
gested that the double-peak phenomenon was related to the
fast and slow release rates of exogenous PTH into the system-
ic circulation following s.c. administration [20, 22].
Serum calcium was assessed not only as a safety endpoint
but also as a PD parameter to support the biosimilarity claim of
RGB-10. Teriparatide is known to cause transient increases in
serum calcium after each dose through increased intestinal ab-
sorption and increased tubular reabsorption of calcium. This is
observed in healthy volunteers and osteoporotic patients and
can therefore be seen as a surrogate marker for the PD effects of
teriparatide. The results for RGB-10 and the reference were
highly similar, with 95% CIs of the GMR of the RGB-10/ref-
erence correcting calcium within 99–101%. The comparable
calcium response for RGB-10 and the reference provides evi-
dence supporting the clinical comparability of these drugs.
The safety profile of RGB-10 was similar to that of the
originator drug with respect to AEs, clinical laboratory mea-
surements, vital signs, electrocardiographic and local toler-
ance assessments. The safety results were comparable to the
data published for teriparatide [23–25], and no differences
were observed between the two treatment groups. There were
no new safety signals reported during this trial, and RGB-10
proved to be as safe as the reference, with no SAEs observed.
Similarly, the incidence and severity of injection site reactions
associated with the use of teriparatide were similar to those
seen in previous studies.
Table 4 Treatment emergent adverse events reported by ≥ 10% of all
subjects
Adverse eventa RGB-10 Reference p valueb
Gastrointestinal disorders 12 (22%) 16 (30%) 0.39
Nausea 10 (19%) 14 (26%) 0.36
Vomiting 4 (7%) 3 (6%) 1.00
General disorders and
administration site conditions
13 (24%) 8 (15%) 0.33
Injection site erythema 9 (17%) 6 (11%) 0.58
Nervous system disorders 10 (19%) 19 (36%) 0.0522
Dizziness 5 (9%) 11 (21%) 0.11
Headache 5 (9%) 11 (21%) 0.11
Presyncope 4 (7%) 3 (6%) 1.00
a Adverse events that occurred during the washout period are attributed to
the treatment from the previous period
b Fisher’s exact test
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A limitation of this study is that immunogenicity could not
be investigated. Establishing pharmacokinetic equivalence
was the primary objective of the trial; consequently, the re-
quirements pertaining to the study design, duration and sam-
ple size laid down in the Guideline on the investigation of
bioequivalence [10] were adhered to. Although satisfying all
the criteria described in the Guideline on the investigation of
bioequivalence [10], the cross-over design, the short study
duration due to the rapid elimination half-life of teriparatide
and the relatively low sample size needed to demonstrate bio-
equivalence all precluded the assessment of immunogenicity.
Nevertheless, the general immunogenic potential of
teriparatide is expected to be low because it is a low molecular
weight, fully human molecule of microbial origin with no
glycosylation or any other posttranslational modifications.
The immunogenic potential of the reference drug proved neg-
ligible in the clinical studies for registration purposes in that
anti-teriparatide antibodies were detected after at least
12 months of treatment in only 2.8% of the patients receiving
20 μg daily s.c. doses of teriparatide [26]; the lack of literature
data on the immunogenicity of the reference product over the
15 years that it has been available on the market seems to
confirm this. Consequently, assessment of the immunogenic
potential of RGB-10 was not among the objectives of the
bioequivalence study.
The strength of the development programme designed for
RGB-10 is that it sets a notable example of the tailored ap-
proach recently adopted by the EMA, in which, for simple
molecules whose mechanism of action is well-established
and where comparative quality and non-clinical data are solid,
comparative PK/PD studies in healthy volunteers may be suf-
ficient to conclude therapeutic equivalence [18].
Given the high level of similarity between RGB-10 and its
reference as demonstrated in the in-depth quality and non-
clinical comparability exercise (data on file) and the BE and
PD comparability established in our clinical study, marketing
authorisation for RGB-10 has been granted for all indications
by the European Medicines Agency (EMA).
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